Abstract
Summary
This is a summary of the latest 2023 European guideline on the diagnosis and management of insomnia disorder in adults aged 18 and older. The guideline provides up-to-date recommendations to healthcare professionals on how best to diagnose, manage, and treat adults with insomnia, focusing on insomnia disorder. Insomnia disorder is defined as a long-term difficulty of falling asleep or staying asleep three or more nights a week for at least three months, despite adequate opportunity for sleep, and which impacts the ability to function well during the day. This summary provides an overview of how insomnia disorder is diagnosed and managed and the recommended treatment options.
Footnotes
Acknowledgements
Writing and editorial support was provided by Jessica Beake, PhD, of Beake Medicom Ltd (UK), funded by Idorsia Pharmaceuticals Ltd. The authors had full control over this summary and provided their final approval of all content. Submission support was provided by Katerina Neou-North with funding from Idorsia Pharmaceuticals Ltd and with the authors’ authorization. Graphic support was provided by Cactus Life Sciences with funding from Idorsia Pharmaceuticals Ltd.
Disclaimer
This summary is for educational purposes and not a substitute for professional medical advice.
Author contributions
L. Palagini contributed to the conceptualization and writing–review, and editing. J.G. Ellis contributed to writing–review, and editing. P.A. Geoffroy contributed to the writing–review, and editing. D. Riemann contributed to the writing–review, and editing. D. Garcia-Borreguero contributed to the conceptualization and writing-review, and editing.
Funding
Idorsia Pharmaceuticals Ltd funded the development of this plain-language summary.
Conflict of Interest Statement
L. Palagini reports speaker and consultant activity for Bruno, Idorsia, Fidia, Neopharmed Gentili, Pfizer, Sanofi, Viatris Pharmanutra. J.G. Ellis is the director of Sleep Research and Consulting Limited. P.A. Geoffroy reports speaker honorara from Biocodex, Bioprojet, Ibsa, Idorsia, Janssen-Cilag, Isis Medical, Pharmanovia, Jazz pharmaceuticals, Lundbeck. He also reports fees for consulting from Apneal, Arrow, Biocodex, Di&Care, Idorsia, Janssen-Cilag, Jazz pharmaceuticals, Myndblue. He also received advisory board honoraria from Apneal, Di&Care, Idorsia, Janssen-Cilag, Myndblue. D. Riemann frequently lectures at conferences, meetings, seminars, mostly invited by the organizing bodies – sometimes honoraria are paid for his engagement and usually travel costs (if travelling is involved) are covered. Most of his talks deal with aspects of insomnia. In the last 36 months D. Riemann received lecturing honoraria also from Novartis and Idorsia. D. Riemann receives honoraria (last 36 months) from GAIA group (Germany), Meinstresscoach (Switzerland), 7Mind (Germany), HelloBetter (Germany), Sympatient (Germany) and X-Trodes (Israel) for advising on the development of internet- based approaches to insomnia treatment and development of new measurement devices. D. Garcia-Borreguero reports consulting with Emalex Biosciences, PsychoGenics Inc., Synendos Therapeutics.